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Abstract
The N-myc downstream-regulated gene 2 (NDRG2) is involved in tumor cell differentiation and apoptosis, but its function in
tumor angiogenesis remains to be established. Here, we employed adenovirus overexpressing NDRG2 (Ad-NDRG2)t o
efficiently up-regulate target gene expression in the NDRG2-low-expressing, breast cancer cell line MCF-7. Moreover, VEGF
secretion was decreased in MCF-7 cells infected by Ad-NDRG2, and medium conditioned by these infected cells could
significantly inhibit the proliferation, tube formation and invasion of human umbilical vein endothelial cells (HUVECs).
Further study indicated that the angiogenesis promoting factors VEGF and HIF-1a were down-regulated, whereas the
angiogenesis suppressing factors p53 and VHL were up-regulated in MCF-7 cells infected by Ad-NDRG2. Finally, in a nude
mouse model, intratumoral injections of Ad-NDRG2 every 3 days for 20 days significantly inhibited the growth and
angiogenesis of xenografted MCF-7 tumors. In summary, these data indicate that NDRG2 may be involved in angiogenesis
by impacting the expression of angiogenesis related factors. Thus, specific overexpression of NDRG2 by adenovirus
represents a promising approach for the treatment of tumor angiogenesis.
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Introduction
Breast cancer neovascularization (BCN), involving both angio-
genesis and vasculogenesis, is a key event in tumorigenesis,
invasion and metastasis. In recent decades, significant progress has
been made toward understanding the pathophysiologic mecha-
nisms of BCN. However, the development of BCN is a
complicated and dynamic process, involving multiple stimuli,
multiple cytokines and multiple cell-type participation, and the
specific mechanisms underlying its progression are largely
unknown.
Hypoxia, a common feature of malignant tumors, can be
detected in central regions of solid tumors as well as during
embryonic development [1]. Hypoxia regulates many transcrip-
tion factors, including hypoxia-inducible factor (HIF)-1a, which
controls hypoxia-induced angiogenic factors such as vascular
endothelial growth factor (VEGF) [2]. VEGF functions as a
survival factor in endothelial cells and tumor cells via VEGF
receptors that are also up-regulated by hypoxia [3]. Thus,
increased VEGF expression by hypoxia, and thereby promotion
of angiogenesis, may be a prerequisite for progressive growth and
metastasis of solid tumors, such as breast cancer. The tumor
suppressor genes p53 and VHL inhibit angiogenesis [4,5].
Mutation or loss of function of these suppressors results in high
vascularization in malignant tumors. VHL and p53 could promote
degradation of HIF-1a by ubiquitin-mediated proteolysis and
suppress HIF-1a-stimulated transcription [6]. VEGF expression is
negatively regulated by p53 and VHL and is frequently
overexpressed along with HIF-1a in human cancers [4,7]. To
understand the interactions between angiogenesis promoting
factors and angiogenesis suppressing factors, it is necessary to
develop treatment strategies that specially target BCN.
NDRG2, a member of the N-myc downstream-regulated gene
family, belongs to the alpha/beta hydrolase superfamily. It was
first cloned in our laboratory from a normal human brain cDNA
library by subtractive hybridization (GenBank accession
no. AF159092) and is regarded as a tumor suppressor gene
(TSG) that is transcriptionally repressed by c-Myc [8,9,10].
Accumulated evidence indicates that NDRG2 is down-regulated
or undetectable in many human cancers [11,12]. The role of
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been shown that breast cancer cells have low or undetectable
expression of NDRG2 compared with the high expression of
NDRG2 in normal tissues [13]. Further studies have found that
NDRG2 is able to inhibit proliferation and enhance apoptosis in
many malignant tumors [14]. In addition, NDRG2 could induce
BMP-4 expression and inhibit the metastatic potential of breast
cancer cells, specifically via suppression of MMP-9 activity [15]. In
our previous study, we have verified also that, as a regulator,
NDRG2 could modulate the process of breast cancer cell adhesion
and invasion through regulating CD24 expression [16]. However,
the specific effect of NDRG2 on breast cancer angiogenesis is still
unknown.
In this study, we first demonstrate that NDRG2 is a regulator
participating in the progression of breast cancer angiogenesis.
Using adenovirus NDRG2 expression, we verified that Ad-NDRG2
could decrease VEGF secretion by MCF-7 cells, and this MCF-7
conditioned medium significantly inhibited HUVEC proliferation,
tube formation and invasion. Furthermore, Ad-NDRG2 up-
regulated the expressions of p53 and VHL while down-regulating
the expressions of VEGF and HIF-1a. Ad-NDRG2 also inhibited
tumor growth and angiogenesis in a nude mouse model. Our
results present a novel role for NDRG2 in the regulation of breast
cancer angiogenesis.
Results
NDRG2 expression in breast cancer cell lines
The tumor suppressor gene NDRG2 is down-regulated or
undetectable in many human cancers. Here, NDRG2 expression in
seven breast cancer cell lines was investigated by western blot and
RT-PCR. The results showed that the expression of NDRG2 was
higher in ZR-751 and T47D cell lines and lower in MDA-MB-231
and MCF-7 cell lines (Fig. 1A). To further determine the role of
NDRG2, we chose to use MCF-7 cells (with wild-type p53) as our
experimental model in the following studies.
NDRG2 up-regulation by Ad-NDRG2 in MCF-7 cells
To evaluate the up-regulation of NDRG2 expression, western
blot and RT-PCR analyses were performed. As shown in
Figure 1B, after infection by Ad-NDRG2, the expression of
NDRG2 was successfully increased at both the protein and mRNA
levels in MCF-7 cells, which express a low level of endogenous
NDRG2.
Suppression of HUVEC proliferation by up-regulating
NDRG2 in MCF-7 cells
To investigate the effect of NDRG2 up-regulation in MCF-7 cells
on HUVEC proliferation, an MTT assay was designed. First,
HUVECs grown in serum-free medium conditioned by MCF-7
cells showed an increase in the proliferation rate, as revealed by
the culture time (Fig. 2A). Next, medium conditioned by Ad-
NDRG2 infected MCF-7 cells markedly inhibited HUVEC
proliferation, which correlated with the conditioning time of the
medium (Fig. 2B). Notably, compared to normoxic conditions,
these effects were much more significant under hypoxic conditions.
Alterations of HUVEC tube formation and invasion by
regulating NDRG2 in MCF-7 cells
To test the effect of NDRG2 on angiogenesis, tube formation
and invasion assays of HUVECs were performed on Matrigel
under hypoxia. Ad-NDRG2 and NDRG2 siRNA (siNDRG2) were
applied respectively to overexpress or knockdown NDRG2. As the
control group, Ad-LacZ-MCF-7 or scramble-MCF-7 cells, HU-
VECs associated with one another and formed microtubes after
6 h. The medium from Ad-NDRG2-MCF-7 cells could repress the
tube formation of HUVECs, but that from siNDRG2-MCF-7 cells
promoted the tube formation of HUVECs (Fig. 3A and 3B). The
invasion assay revealed that the medium from Ad-NDRG2-MCF-7
cells inhibited HUVECs’ invasion ability; however, that from
siNDRG2-MCF-7 cells increased a lot compared with the Ad-
LacZ-MCF-7 or scramble-MCF-7 cells respectively (Fig. 3C and
3D). These data raised the possibility that NDRG2 overexpression
or knockdown in MCF-7 cells might mediate the production of
extracellular matrix components that in turn are involved in the
tube formation and invasion of HUVECs.
Regulation of the expression of hypoxia-induced,
angiogenesis related factors by up-regulation of NDRG2
in MCF-7 cells
To further explore whether products of resulting from NDRG2
up-regulation in MCF-7 cells may be responsible for inhibition of
HUVEC growth, we measured the VEGF level in cell culture
medium under normoxic or hypoxic conditions. ELISA assay
results showed that, compared to normoxic conditions, hypoxia
could significantly increase VEGF secretion into the cell culture
medium in a time-dependent manner (Fig. 4A). Furthermore,
VEGF secretion was decreased in MCF-7 cells infected by Ad-
Figure 1. Expression of NDRG2 in breast cancer cell lines and the effect of Ad-NDRG2. (A) T-47D, MCF-7, BCAP-37, HBL-100, ZR-751, SK-BR-3
and MDA-MB-231 cells were collected for extraction of protein and RNA and analyzed for NDRG2 expression using western blot and RT-PCR. (B)
NDRG2 low-expression MCF-7 breast cancer cells were infected by adenovirus carrying NDRG2 (Ad-NDRG2) or negative control LacZ (Ad-LacZ).
Thereafter, protein and RNA from these cells were extracted and subjected to western blot and RT-PCR analysis. b-actin was used as a loading control.
The data are representative of three independent experiments.
doi:10.1371/journal.pone.0032368.g001
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conditions (Fig. 4B). To determine whether these hypoxia-
induced, angiogenesis related factors are involved in NDRG2-
mediated cell activities in breast cancer, western blot was
performed to examine the expression levels of these factors. The
results showed that HIF-1a expression was decreased in Ad-
NDRG2-MCF-7 cells, and this was in accordance with the
decreased VEGF secretion. In contrast to the effect on VEGF
and HIF-1a, the expressions of p53 and VHL were up-regulated
by Ad-NDRG2 under hypoxia (Fig. 4C). Thus, it is possible that
NDRG2 influences HIF-1a and VEGF expression by indirectly
regulating p53 and VHL expression or by directly controlling the
transcription of HIF-1a and VEGF.
Suppression of tumor growth and angiogenesis in a
nude mouse model by intratumoral injection of Ad-
NDRG2
To investigate the effects of Ad-NDRG2 on tumor growth and
angiogenesis in vivo, we injected 1610
9 PFU Ad-NDRG2, Ad-LacZ
or PBS every 3 days into pre-established, human MCF-7 breast
tumors (approximately 200 mm
3) grown in nude mice. As shown
in Figure 5A, the Ad-NDRG2 group achieved a sustained and
significant arrest of tumor growth (71% decrease in mean tumor
volume on day 21 compared with the control group), whereas the
growth of tumors injected with Ad-LacZ was not significantly
inhibited (3.4% decrease compared with the control group). The
mice were sacrificed at 21 days after beginning intratumoral
injections, and the tumors were removed for analysis of the
vascularization. Immunolabeling for VEGF and HIF-1a were
lower in tumors excised from mice in the Ad-NDRG2 group.
Moreover, the p53 and VHL expression levels in the Ad-NDRG2
group were dramatically increased dramatically compared to the
control group. The microvessel density (MVD) of the tumors was
examined after immunolabeling for CD31, a typical vascular
endothelial cell marker. In the Ad-NDRG2 group, the MVD of the
tumors was inhibited compared with the control and Ad-LacZ
groups. There was no significant difference between the control
and Ad-LacZ groups (Fig. 5B and 5C).
Discussion
Although surgical resection, adjuvant and endocrine therapy
are commonly used to treat breast cancer patients, the overall
survival rate for breast cancer requires improvement. Therefore,
the development of biological therapies for breast cancer is
urgently required. Recent reports have shown, in breast cancer
patients, that NDRG2 expression is significantly reduced
compared to breast normal tissue [13]. Further studies have
found that NDRG2 inhibits the proliferation, adhesion and
invasion of breast cancer cells [14,16]. In addition, our previous
study found that NDRG2 could inhibit the metastatic potential of
breast cancer cells, specifically via suppression of CD24 or
MMP-9 expression [16]. Interestingly, silencing NDRG2 atten-
uates p53-mediated apoptosis, whereas overexpression of
NDRG2 suppresses tumor cell growth regardless of the presence
or absence of p53 [14]. Therefore, NDRG2 is required for p53-
mediated apoptosis but not for proliferation. These data indicate
that an association exists between NDRG2 expression and
reduced breast cancer malignant behavior and that NDRG2
may be a novel target for future biological therapies for breast
cancer. However, to date, the roles of NDRG2 in breast cancer
angiogenesis have not been explored. In this paper, our data
revealed that NDRG2 overexpression in breast cancer cells could
suppress HUVEC proliferation, tube formation and invasion by
reducing VEGF and HIF-1a expression and increasing p53 and
VHL expression. Importantly, tumor growth and angiogenesis in
a nude mouse model were inhibited by intratumoral injection of
Ad-NDRG2.
Recently, several reports have shown that NDRG2 is a target
gene of HIF-1a, and hypoxia treatment dramatically up-regulated
NDRG2 expression in many human cancer cell lines [17,18].
Knockdown of HIF-1a expression did not change NDRG2
expression but could abolish hypoxia-induced up-regulation of
NDRG2. In our study, infection by Ad-NDRG2 reduced HIF-1a
expression in a time-dependent manner in MCF-7 cells. Based on
these results, we believe that NDRG2 is a hypoxia-regulated gene,
NDRG2 and HIF-1a could regulate each other, and there might be
feedback loops between them. Furthermore, our data showed that
VEGF secretion was decreased in MCF-7 cells infected by Ad-
NDRG2 in a time-dependent manner, especially under hypoxic
conditions. This suggests that NDRG2 may be involved in hypoxia-
induced angiogenesis.
Loss of wild type p53 and VHL could promote angiogenesis by
relieving inhibition of VEGF production. Several findings
demonstrated that p53 and VHL could inhibit VEGF expression
by regulating the transcriptional activity of Sp1 and by down-
regulating Src kinase activity under hypoxia [19,20]. Moreover,
both p53 and VHL can promote the degradation of HIF-1a to
indirectly suppress VEGF expression [21,22,23]. There is evidence
Figure 2. Effect of MCF-7 preconditioned media on HUVEC
proliferation. (A) HUVECs were grown to confluence and were then
cultured in preconditioned media (derived from MCF-7 and Ad-LacZ-
MCF-7 cells pretreated under normoxia and hypoxia for 24 or 48 h) for
24 h, and serum-free DMEM was used as a control. (B) HUVECs were
grown to confluence and were then cultured in preconditioned media
(derived from Ad-LacZ-MCF-7 or Ad-NDRG2-MCF-7 cells pretreated
under normoxia and hypoxia for 24 or 48 h) for 24 h. Ad-LacZ -MCF-
7(N) or Ad-LacZ-MCF-7 (H) was used as controls. N, normoxia; H,
hypoxia. The data are the mean 6 standard deviation (SD) for three
independent experiments. Statistical significance was assessed using
one-way ANOVA and Student’s t-test. * or ** indicates P,0.05 or
P,0.01, respectively, when compared with the control.
doi:10.1371/journal.pone.0032368.g002
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p53 and VHL and is frequently overexpressed along with HIF-1a
in human cancers.
The present study has shown that NDRG2 overexpression in
breast cancer cells can inhibit the proliferation, tube formation
and invasion of HUVECs, preventing the participation of these
cells in hypoxia-induced, tumor angiogenesis. This effect may be
related to the inhibition of VEGF secretion. Both in vitro and in vivo
up-regulation of NDRG2 by Ad-NDRG2 increased p53 and VHL
expression and decreased VEGF expression. It is possible that the
down-regulation of VEGF by NDRG2 overexpression might be the
consequence of the up-regulation of the tumor suppressor genes
p53 and VHL. In summary, our results provide the first evidence
that NDRG2 contributes to breast cancer angiogenesis by
controlling the expression of angiogenesis related factors. Further
investigation into the molecular mechanism of NDRG2 action may
offer a novel approach for treating breast cancer, specifically by
targeting breast cancer angiogenesis.
Figure 3. Effect of MCF-7 preconditioned media on HUVEC tube formation and invasion. (A and B) The tube formation assay was
performed as described in Material and Methods. HUVECs were plated on Matrigel and incubated under hypoxia for 6 h. Tube lengths were
measured with Image-Pro Plus software; the histograms represent the quantification of the tube length of HUVECs. (C and D) The invasion assay was
performed as described in Material and Methods. After 4 h under hypoxia, the amount of invaded cells was calculated in five random high-power
fields (4006), and the number from the control group was used as a control. The histogram represents the quantification of cells that invaded. The
data are the mean 6 standard deviation (SD) for three independent experiments. Statistical significance was assessed using one-way ANOVA and
Student’s t-test. * or ** indicates P,0.05 or P,0.01, respectively, when compared with the control.
doi:10.1371/journal.pone.0032368.g003
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Cell lines and reagents
Human breast cancer cell lines T-47D, MCF-7, BCAP-37,
HBL-100, ZR-751, SK-BR-3 and MDA-MB-231, were obtained
from the American Type Culture Collection (ATCC, USA) and
cultured according to their directions and guidelines. Human
umbilical vein endothelial cells (HUVECs) were obtained and
cultured as described previously [21,22]. HUVECs were
suspended in HuMedia-EG2 medium (Kurabo Industries) and
then plated on plastic culture dishes. HuMedia-EG2 medium
consisted of the base medium (HuMedia-EB2) supplemented with
2% fetal bovine serum, 10 ng/ml hEGF, 5 ng/ml hFGF-B,
1 mg/ml hydrocortisone, 50 mg/ml gentamicin, 50 ng/ml am-
phatericin B, and 10 mg/mL heparin. The cells were maintained
at 37uC in a humidified atmosphere containing 5% CO2.B e f o r e
experiments, cells were cultured under serum-free conditions in
M199 medium for 18 to 24 h. For hypoxia treatment, cells were
cultured under hypoxic conditions (1% O2,5 %C O 2 and 94%
N2) and harvested at different times. Anti-NDRG2 (1:500 dilution)
antibodies were purchased from BD Corporation (BD, NY,
USA). Anti-HIF-1a (1:200 dilution) and anti-p53 (1:1000
dilution) antibodies, and ECL reagents were from Santa Cruz
Technology (Santa Cruz, CA, USA). Anti-VHL antibody (1:200
dilution) was from Neomarkers Corporation (Taipei, China).
Anti-b-actin antibody (1:5000 dilution) was from Sigma (Sigma,
USA).
Gene infection
A multiplicity of infection (MOI) of 40 was determined
experimentally for MCF-7 cells. Cells were seeded in 6-well plates
at a density of 5610
5 cells/well and incubated to reach
approximately 80% confluence. After removing the medium,
adenovirus expressing NDRG2 (Ad-NDRG2) or the negative control
gene LacZ (Ad-LacZ) was added in serum-free DMEM, incubated
for 2 h, replaced with fresh DMEM supplemented with 10% FBS
and incubated for 48 h.
Gene transfection
MCF-7 cells were seeded in 6-well plates at a density of 5610
5
cells/well and incubated to reach approximately 80% confluence.
The gene transfection assay was performed with the following
constructs using Lipofectamine 2000 (Invitrogen, Carlsbad, Calif)
according to the manufacturer’s instructions: a small interfering
RNA (siRNA) that targeted NDRG2 (siNDRG2: forward, GCU-
CUCUGGAAAUUCUGAGUUGAUA; reverse, UUAAGAGC-
AUAUCUCGCCAGGAUGU) and its scramble siRNA (scram-
ble: forward, UUCUCCGAACGUGUCACGUTT; reverse, AC-
GUGACACGUUCGGAGAATT; Biomics Inc., AgouraHills,
Calif). Cells were exposed to siRNA in DMEM for 6 h, after
Figure 4. Effect of Ad-NDRG2 on the expression of VEGF, HIF-1a, p53, and VHL under normoxia or hypoxia. (A) MCF-7 cells were
incubated for the indicated time (0, 6, 12, 24, 36 h) in normoxic (21% O2) or hypoxic (1% O2) conditions. After incubation, the media were analyzed for
VEGF levels by ELISA assay, and the cell number was counted. (B) MCF-7, Ad-LacZ-MCF-7 and Ad-NDRG2-MCF-7 cells were incubated for the indicated
time (24, 48 h) in normoxic or hypoxic conditions. After incubation, the media were analyzed for VEGF levels by ELISA assay, and the cell number was
counted. The data are the mean 6 standard deviation (SD) for three independent experiments. Statistical significance was assessed with one-way
ANOVA and Student’s t-test. * or ** indicates P,0.05 or P,0.01, respectively, when compared with the normoxia or Ad-LacZ-MCF-7 group. N,
normoxia; H, hypoxia. (C) MCF-7, Ad-LacZ-MCF-7 and Ad-NDRG2-MCF-7 cells were incubated under hypoxia for 0, 12, or 24 h. After incubation, the
cells were analyzed by western blot assay. b-actin protein levels were used as a loading control.
doi:10.1371/journal.pone.0032368.g004
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FBS and the cells were incubated for 48 h.
RT-PCR
RNA extracted from cells with Trizol reagent (Invitrogen, Life
Technologies, US) was converted to cDNA using the RevertAid
TM
First Strand cDNA Synthesis Kit (Fermantas, CA). Total RNA
(5 mg) was then reverse transcribed into cDNA using an AMV
reverse transcriptase (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. The cDNA was subjected to PCR
amplification using the following primers: NDRG2,5 9-ATGGCG-
GAGCTGCAGGAGGTGC-39 (sense) and 59-TGAGGAACG-
AGGTCTGGGTGGG-39 (antisense); b-actin, 59-GATCATT-
GCTCCTCCTGAGC-39 (sense) and 59- TGTGGACTTGGGA-
GAGGACT- 39 (antisense). The PCR mixture (25 ml) containing a
Taq polymerase from Promega was denatured at 94uC for 5 min,
followed by 35 cycles of 94uC for 30 s, 60uC for 30 s and 72uC for
30 s, with a final extension at 72uC for 10 min. The PCR products
were separated in 3% agarose gels by electrophoresis and
visualized with ethidium bromide under a UV light.
Western blot
MCF-7 cells were homogenized in RIPA lysis buffer and
insoluble material was removed by centrifugation at 4uC. From
each sample, 80–100 mg of total protein extract was resolved by
12% SDS-PAGE and transferred to nitrocellulose membranes
(Amersham Biosciences, Piscataway, NJ). The membranes were
blocked in 5% milk and probed with the antibodies overnight at
4uC. Membranes were washed and incubated with a horseradish
peroxidase (HRP)-conjugated secondary antibody (Santa Cruz
Biotech) for 1 h at 37uC. Chemiluminescent HRP substrate
solution (Millipore, USA) was used to develop the images.
MTT assay
HUVECs were plated at a density of 4610
4 cells/cm
2 in 24-well
plates in complete medium and allowed to adhere overnight. The
conditioned culture medium from MCF-7 cells was placed in the
wells, and the whole plate was incubated in a hypoxic chamber.
HUVEC proliferation was measured using a modified MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. After
the inserts were removed, 100 ml MTT was added per well, and
HUVECs were incubated for 4 h. The formazan crystals formed
were dissolved in 750 ml dimethyl sulfoxide after the medium was
aspirated. The solution was transferred to a 96-well plate and the
optical density valuewasrecorded at570 nmona MicroplateReader
(Model 680, Bio-Rad, USA). The results were expressed relative to
the OD value of HUVEC monocultures on day 1 of the assay.
ELISA assay
To assess VEGF secretion in the supernatants of infected cells,
the cells were incubated in serum-free medium under normoxia or
hypoxia. After 0–36 h, the media were collected, centrifuged to
remove cellular debris, and stored at 270uC until assayed for
VEGF. VEGF secreted in the culture medium was measured by
ELISA according to the manufacturer’s instructions. Data were
expressed in pg VEGF/10
5 cells/ml.
Tube formation assay
Sterile 24-well plates were coated with 200 ml Matrigel and
incubated at 37uC for 1 h to form gels. After polymerization of the
gels, 1.0610
5 HUVECs were seeded into each well and incubated
with 1.0 ml DMEM containing 1% FBS. Next, media from MCF-
7 cells were placed in the wells under hypoxia for 6 h. Five
different fields were chosen randomly in each well, and
photographs were taken. The length of the tubes was measured
using Image-Pro Plus software (Media Cybernetics, L.P., Silver
Spring, MD, USA) and was expressed as total length (mm) per
microscopic field for each well.
Invasion assay
The HUVECs migration assay was performed using Matrigel-
coated, Costar Transwell inserts with an 8 mm pore-size. Briefly,
5.0610
4 HUVECs were seeded onto inserts and incubated with
M199 medium containing 1% FBS. After a 1 h attachment, the
inserts were transferred to 24-well plates containing media from
Ad-LacZ-MCF-7 or Ad-NDRG2-MCF-7 cells. After incubation for
4 h under hypoxic condition, the inserts were fixed with 4%
paraformaldehyde and stained with hematoxylin and eosin. The
number of invaded cells was counted using phase contrast
microscopy (4006). Five randomly chosen fields were counted
per insert.
Xenograft study in nude mice
For inoculation into nude mice, MCF-7 cells were washed with
PBS, digested with trypsin, and resuspended in serum-free DMEM
medium. After centrifugation (800 rpm), cell pellets were resus-
pended in DMEM. The cell suspension (5610
6 cells in a volume of
100 ml PBS) was injected subcutaneously into the hind legs of 4-
week-old female BALB/C athymic (nu/nu) mice (SLAC Labora-
tory Animal Company, Shanghai, China) [24]. When tumors
reached a volume of 200 mm
3, the mice were arbitrarily assigned
to different groups (n=6 each) to receive intratumoral injections of
10
9 PFU Ad-NDRG2, Ad-LacZ, or PBS. Intratumoral injections
were repeated every 3 days for a total of 20 days. Tumors were
measured (perpendicular diameters) every day and their volumes
calculated. On day 20, the mice were sacrificed and their tumors
removed for analysis. Tumor volumes were calculated based on
caliper measurements of the length and width of the lesions using
the following formula: 0.56length6width
2. The growth curve was
then derived from these data.
All the experimental procedures were conducted in accordance
with the Detailed Rules for the Administration of Animal
Experiments for Medical Research Purposes issued by the
Figure 5. Effects of intratumoral injections of Ad-NDRG2 on the growth and vascularization of MCF-7 cell xenografts in mice. These
experiments were described in ‘‘Materials and Methods’’. (A) Tumor growth curve. The tumor growth was assessed every 3 days until Day 21 of
treatment by measuring two perpendicular diameters and calculating the volume in mm
3. Statistical analysis was performed using Day 21 values
only, with one-way ANOVA and Student’s t-test. ** indicates P,0.01 when compared with the control. The typical photographs of tumors are shown.
(B) Intratumoral vascularization was assessed by VEGF, p53, VHL, and HIF-1a immunolabeling (4006magnification) on paraffin-embedded MCF-7 cell
tumor sections. Representative images are shown. (C) Integrated optical density (IOD) values of VEGF, p53, VHL, HIF-1a protein expression and MVD
of the tumors were evaluated. ImagePro Plus software was utilized to analyze the IOD values of the positive areas of immunohistochemical staining,
and the resulting histograms are shown. After areas containing dense vascularity, either within the tumor or during different pathological stages,
were selected using a microscopic field with 1006power, all brown-stained vessels were counted under three fields with 2006power. The mean
value of the vessels in the three fields was taken as the MVD count of a tumor. The histograms are shown. Statistical analysis was carried out using
one-way ANOVA. The results are shown as the mean 6 SD from a total of six mice. *P,0.05 or **P,0.01.
doi:10.1371/journal.pone.0032368.g005
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Animal Experiment Administration Committee of the Fourth
Military Medical University (Xi’an, P. R. China). All efforts were
made to minimize the animals’ suffering and to reduce the number
of animals used.
Immunohistochemistry
Immunohistochemical staining was performed to assess the
protein expression of VEGF, HIF-1a, VHL, p53 and CD31, as
described previously [25]. For immunohistochemistry, formalin-
fixed tumor tissues were embedded in paraffin, and serial 4 mm
sections were obtained using a Leica microtome. For staining,
tumor sections were dewaxed in toluene, rehydrated in an alcohol
gradient, permeabilized in citrate buffer (pH 6.0), quenched with
3% H2O2 for 5 min to eliminate endogenous peroxidase activity,
washed in PBS, incubated overnight with different antibodies and
then with biotinylated goat anti-rat or anti-rabbit IgG antibody for
15 min. After washing, sections were incubated with streptavidin–
peroxidase, lightly counterstained with hematoxylin, and observed
under a photomicroscope.
Statistical analysis
SPSS 13.0 software was used to perform statistical analyses.
Data are presented as the mean 6 SD, and statistical comparisons
between groups were made using one-way ANOVA followed by
Student’s t-test. P,0.05 was considered statistically significant.
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